###begin article-title 0
###xml 92 96 <span type="species:ncbi:10090">Mice</span>
Pharmacological Stimulation of NADH Oxidation Ameliorates Obesity and Related Phenotypes in Mice
###end article-title 0
###begin p 1
J.H.H. and D.W.K. contributed equally to this work.
###end p 1
###begin title 2
OBJECTIVE
###end title 2
###begin p 3
###xml 39 40 39 40 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 124 125 124 125 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 244 245 244 245 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
Nicotinamide adenine dinucleotides (NAD+ and NADH) play a crucial role in cellular energy metabolism, and a dysregulated NAD+-to-NADH ratio is implicated in metabolic syndrome. However, it is still unknown whether a modulating intracellular NAD+-to-NADH ratio is beneficial in treating metabolic syndrome. We tried to determine whether pharmacological stimulation of NADH oxidation provides therapeutic effects in rodent models of metabolic syndrome.
###end p 3
###begin title 4
RESEARCH DESIGN AND METHODS
###end title 4
###begin p 5
###xml 357 362 345 350 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ob/ob</italic>
###xml 244 248 <span type="species:ncbi:10090">mice</span>
###xml 363 367 <span type="species:ncbi:10090">mice</span>
We used beta-lapachone (betaL), a natural substrate of NADH:quinone oxidoreductase 1 (NQO1), to stimulate NADH oxidation. The betaL-induced pharmacological effect on cellular energy metabolism was evaluated in cells derived from NQO1-deficient mice. In vivo therapeutic effects of betaL on metabolic syndrome were examined in diet-induced obesity (DIO) and ob/ob mice.
###end p 5
###begin title 6
RESULTS
###end title 6
###begin p 7
###xml 511 515 <span type="species:ncbi:10090">mice</span>
NQO1-dependent NADH oxidation by betaL strongly provoked mitochondrial fatty acid oxidation in vitro and in vivo. These effects were accompanied by activation of AMP-activated protein kinase and carnitine palmitoyltransferase and suppression of acetyl-coenzyme A (CoA) carboxylase activity. Consistently, systemic betaL administration in rodent models of metabolic syndrome dramatically ameliorated their key symptoms such as increased adiposity, glucose intolerance, dyslipidemia, and fatty liver. The treated mice also showed higher expressions of the genes related to mitochondrial energy metabolism (PPARgamma coactivator-1alpha, nuclear respiratory factor-1) and caloric restriction (Sirt1) consistent with the increased mitochondrial biogenesis and energy expenditure.
###end p 7
###begin title 8
CONCLUSIONS
###end title 8
###begin p 9
###xml 96 100 <span type="species:ncbi:10090">mice</span>
Pharmacological activation of NADH oxidation by NQO1 resolves obesity and related phenotypes in mice, opening the possibility that it may provide the basis for a new therapy for the treatment of metabolic syndrome.
###end p 9
###begin p 10
###xml 160 161 160 161 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B1">1</xref>
###xml 472 473 472 473 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B2">2</xref>
###xml 617 618 617 618 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B3">3</xref>
###xml 642 643 642 643 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B4">4</xref>
###xml 905 906 893 894 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B5">5</xref>
###xml 906 906 894 894 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B6"/>
###xml 906 906 894 894 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B7"/>
###xml 907 908 895 896 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B8">8</xref>
###xml 1036 1037 1024 1025 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B9">9</xref>
###xml 1038 1040 1026 1028 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B10">10</xref>
Metabolic syndrome comprises a constellation of specific cardiovascular disease risk factors whose underlying pathophysiology is related to insulin resistance (1). All the components of metabolic syndrome such as dyslipidemia, high blood pressure, glucose intolerance, and liver and muscle fat infiltration are related to central obesity. It has been reported that the imbalance between energy intake and expenditure is clearly related to obesity and metabolic disorders (2). Less calorie intake and more energy expenditure through exercise are the most effective modalities for the prevention of metabolic syndrome (3). Calorie restriction (4) and increased physical activity, in fact, have been known to prevent and reverse the phenotypes of metabolic syndrome by activating metabolic regulator proteins such as Sirt1, AMP-activated protein kinase (AMPK), and PPARgamma coactivator-1alpha (PGC-1alpha) (5-8). The protective effects of these proteins against metabolic syndrome are closely linked to increased mitochondrial functions (9,10).
###end p 10
###begin p 11
###xml 76 77 76 77 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 136 138 136 138 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B11">11</xref>
###xml 139 141 139 141 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B12">12</xref>
###xml 183 184 183 184 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 287 288 287 288 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B5">5</xref>
###xml 492 494 488 490 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B10">10</xref>
###xml 769 770 765 766 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 916 917 912 913 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
Previous studies have indicated that nicotinamide adenine dinucleotides (NAD+ and NADH) are fundamental mediators of energy metabolism (11,12). An increased intracellular level of NAD+ activates Sirt1-dependent metabolic control, mediating the effects of calorie restriction in mammals (5). Moreover, pharmacological activation of Sirt1 prevents development of metabolic syndrome through the synergistic activation of AMPK and PGC-1alpha, which results in elevated mitochondrial respiration (10). Mitochondrial NADH is a critical electron donor in mitochondrial electron transport chain, and cytosolic NADH can be shuttled into mitochondria, thereby affecting mitochondrial oxidative phosphorylation. Based on these ideas, we hypothesized that transiently increased NAD+ levels coupled with decreased NADH levels in cytosol provoke mitochondrial oxidative phosphorylation and that long-term induction of a higher NAD+-to-NADH ratio mimics the effects of calorie restriction.
###end p 11
###begin p 12
###xml 181 187 181 187 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F1">Fig. 1</xref>
###xml 187 188 187 188 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</italic>
###xml 191 193 191 193 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B13">13</xref>
###xml 363 365 357 359 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B14">14</xref>
###xml 760 761 748 749 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
NADH:quinone oxidoreductase 1 (NQO1) is a cytosolic antioxidant flavoprotein that catalyzes the reduction of highly reactive quinone metabolites by using NADH as an electron donor (Fig. 1A) (13). A naturally occurring compound, beta-lapachone (betaL) is a substrate of NQO1 and its treatment to cancer cells results in depletion of NADH and consequent apoptosis (14). ArQule (ARQ) 501, a synthetic version of betaL, is a promising anticancer drug currently in multiple phase II clinical trials. Its anticancer action is based on the findings that cancer cells usually exhibit a high level of NQO1 expression. In this study, we investigate the effect of betaL on the metabolic syndrome of rodent models to examine whether pharmacological induction of a high NAD+-to-NADH ratio is beneficial in treating the key components of metabolic syndrome.
###end p 12
###begin p 13
###xml 127 128 124 125 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</italic>
###xml 271 272 265 266 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</italic>
###xml 429 430 420 421 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 452 453 443 444 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 571 598 562 589 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">research design and methods</sc>
###xml 646 647 637 638 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</italic>
###xml 866 867 846 847 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">D</italic>
###xml 923 926 900 903 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/&#8722;</sup>
###xml 935 938 912 915 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 1034 1037 1007 1010 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/&#8722;</sup>
###xml 1046 1049 1019 1022 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 1200 1201 1169 1170 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E</italic>
###xml 1286 1289 1255 1258 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/&#8722;</sup>
###xml 1298 1301 1267 1270 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 1427 1429 1392 1394 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">14</sup>
###xml 1431 1432 1396 1397 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 1458 1461 1423 1426 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">F&#8211;H</italic>
###xml 1482 1483 1447 1448 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">F</italic>
###xml 1493 1494 1458 1459 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">G</italic>
###xml 1511 1513 1476 1478 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">14</sup>
###xml 1539 1540 1504 1505 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">H</italic>
###xml 1613 1614 1575 1576 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 1625 1626 1587 1588 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
betaL-induced NADH oxidation stimulates the AMPK signaling pathway and mitochondrial fuel metabolism in NQO1-expressing cells. A: Schematic illustration of NQO1-mediated chemical reaction. NADH is oxidized by providing two electrons to betaL, which is catalyzed by NQO1. B: L6 myoblasts were treated with the indicated concentration of betaL for 30 min and extracted in lysis buffer containing 80% ice-cold methanol/water (MtOH/H2O). Representative NAD+-to-NADH ratios were determined by liquid chromatography-mass spectroscopy/mass spectroscopy analysis as described in research design and methods. All experiments were performed in triplicate. C: betaL-induced phosphorylations of AMPKalpha and ACC. Immunoblot analyses of the lysates from MEF treated with betaL (5 mumol/l) for the indicated time periods were performed with antibodies to the indicated proteins. D: Phosphorylation and activation of AMPK by betaL in NQO+/- and NQO1-/- MEFs. Phosphorylation of AMPKalpha was estimated by immunoblot analyses of the lysates from NQO+/- and NQO1-/- MEF treated with betaL (5 mumol/l) or DMSO for 30 min, and the activity of AMPK was measured by using the SAMS peptide assay. Error bars indicate SD. E: Phosphorylation of ACC was estimated by immunoblot analyses of the lysates from NQO+/- and NQO1-/- MEF treated with betaL (5 mumol/l) or DMSO for 30 min, and the activity of ACC was determined by quantifying the fixation of 14CO2 to acid-stable products. F-H: Comparison of CPT (F), 3-HAD (G) activities, or 14C-palmityl-CoA oxidation (H) between DMSO- and betaL-treated L6 myoblasts. Error bars indicate SD (*P < 0.05; **P < 0.005).
###end p 13
###begin title 14
RESEARCH DESIGN AND METHODS
###end title 14
###begin title 15
Animal models.
###end title 15
###begin p 16
###xml 260 265 260 265 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ob/ob</italic>
###xml 209 213 <span type="species:ncbi:10118|species:ncbi:10116">rats</span>
###xml 278 282 <span type="species:ncbi:10090">mice</span>
###xml 462 466 <span type="species:ncbi:10090">mice</span>
###xml 575 579 <span type="species:ncbi:10090">mice</span>
###xml 807 812 <span type="species:ncbi:10090">mouse</span>
###xml 873 877 <span type="species:ncbi:10090">mice</span>
All animal procedures were in accordance with the guidelines issued by the Institutional Animal Care and Use Committee of the Chungnam National University School of Medicine. Otsuka Long Evans Tokushima fatty rats were from the Otsuka Research Institute. Male ob/ob and C57BL/6 mice were from The Jackson Laboratory and housed four per cage in a room maintained at a constant temperature (25degreesC) in a light:dark 12:12-h schedule. Four-week-old male C57BL/6 mice were fed a high-fat diet (Research Diets, 24% [w/w], 45% calories as fat) ad libitum for 7 weeks. Groups of mice were untreated, vehicle treated (calcium silicate), pair fed, or betaL treated (p.o., micronized particles of betaL coated with calcium silicate). Body weight and food intake were measured daily. At the end of experiments, one mouse from each group was anesthetized and examined by MRI. Other mice were dissected, and tissue weight was measured.
###end p 16
###begin title 17
Antibodies, plasmids, and reagents.
###end title 17
###begin p 18
Anti-AMPKalpha antibody was purchased from Cell Signaling Technology (for immunoblotting) and Upstate (for immunoprecipitation). Anti-phospho-T172 AMPKalpha, anti-acetyl-CoA carboxylase (ACC), and anti-phospho-S79 ACC antibodies were from Cell Signaling Technology. Anti-NQO1 antibody was from Santa Cruz Biotechnology. Anti-OxPhos Complex II subunit antibody was from Molecular Probes. Anti-alpha-tubulin antibody was from Sigma. pEFIRES HA-NQO1, and pEFIRES HA-NQO1C609T plasmids were gifts from Dr. Gad Asher (Weizmann Institute of Science, Rehovot, Israel). Other reagents were purchased from Sigma, Calbiocam, or Amresco.
###end p 18
###begin title 19
Liquid chromatography-mass spectroscopy/mass spectroscopy analysis.
###end title 19
###begin p 20
###xml 98 99 97 98 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 570 572 562 564 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B15">15</xref>
###xml 759 761 745 747 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B15">15</xref>
###xml 932 933 918 919 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4</sub>
###xml 959 960 945 946 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B4">4</xref>
###xml 1416 1418 1402 1404 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">18</sub>
###xml 1496 1498 1481 1483 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B16">16</xref>
Cell extracts were prepared in 200 mul lysis buffer containing 80% ice-cold methanol/water (MtOH/H2O). The cells were subjected to ultrasonication with a sonic Dismembator (Fisher Scientific, Fairland, NJ) on a power setting of 3 for 30 s. After centrifugation at 12,000 rpm for 10 min, the supernatant was filtered through a Microcon YM-3 filter (Millipore, Bedford, MA) at 4degreesC for 40 min and evaporated down to dryness using a Vacufuge Concentrator before reconstitution in 50 mul of water. The chromatographic system was set up as described in a previous work (15) with minor modifications. The mass spectrometer was operated in the negative ion mode with an electrospray voltage of 4,000 V at 300degreesC and was supplied by auxiliary gas (30 psi) (15). Quantification was performed with Xcalibur software (Thermo Fisher Scientific) using the standard addition method. Liver samples were extracted by perchloric acid (HClO4) or potassium hydroxide (4) solution to determine adenine and oxidized and reduced pyridine nucleotide contents, respectively. Electrospray-ionization mass spectrometry was performed in positive ion mode using a MDS Sciex API 4000 Triple Quadrupole Mass Spectrometer (Applied Biosystems, Ontario, Canada) followed by chromatographic separation on an Agilent 1100 series high-performance liquid chromatography system (Agilent Technologies, Palo Alto, CA) equipped with an XTerra MS C18 2.1 x 150 mm, 3.5-mum column (Waters, Milford, MA), as previously described (16).
###end p 20
###begin title 21
Histochemistry and electron microscopy.
###end title 21
###begin p 22
###xml 324 326 323 325 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B17">17</xref>
###xml 0 5 <span type="species:ncbi:10090">Mouse</span>
Mouse tissues were fixed with formalin, dehydrated with ethanol, embedded in paraffin, and cut at a thickness of 5 mumol/l. Sections of epididymal fat, liver, soleus muscle, and extensor digitorum longus (EDL) were prepared for hematoxylin and eosin staining. Liver and muscle tissues were prepared as described previously (17) for transmission electron microscopy (Tecnai G2 Spirit Twin; FEI Company; Korea Basic Science Institute).
###end p 22
###begin title 23
Enzyme assays.
###end title 23
###begin p 24
###xml 125 127 125 127 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B14">14</xref>
###xml 337 339 333 335 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">32</sup>
###xml 370 372 366 368 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B18">18</xref>
###xml 433 435 429 431 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">14</sup>
###xml 437 438 433 434 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 464 466 460 462 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B19">19</xref>
###xml 547 549 543 545 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">14</sup>
###xml 649 651 645 647 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B19">19</xref>
###xml 779 780 775 776 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">l</sc>
###xml 846 847 842 843 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 911 913 907 909 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B20">20</xref>
###xml 40 45 <span type="species:ncbi:10090">mouse</span>
Cytoplasmic extracts were prepared from mouse tissues for enzyme assays. NQO1 activity was measured as described previously (14). This method measures the decrease in absorbance at 600 nm as a result of the reduction of 2,6-dichlorophenolindophenol. Total AMPK activity was measured using a synthetic "SAMS" peptide substrate and [gamma-32P]ATP as described previously (18). ACC activity was estimated by quantifying the fixation of 14CO2 to acid-stable products (19). Carnitine palmitoyltransferase (CPT) activity was measured by the transfer of 14C-carnitine into the mitochondria matrix in L6 myoblasts and soleus muscle as described previously (19). Hydroxyacyl-CoA dehydrogenase (HAD) activity was measured in L6 myoblasts by monitoring the conversion of acetoacetyl-CoA to l-3-hydroxybutyryl CoA and the concomitant oxidation of NADH to NAD+. The reaction was monitored at 340 nm as described previously (20).
###end p 24
###begin title 25
Analysis of fatty acid oxidation and malonyl-CoA concentration.
###end title 25
###begin p 26
###xml 0 2 0 2 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">14</sup>
###xml 104 106 101 103 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">14</sup>
###xml 108 109 105 106 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 171 173 168 170 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B20">20</xref>
###xml 268 270 265 267 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B21">21</xref>
14C-palmityl-CoA (Perkin Elmer) oxidation by betaL was measured in L6 myoblasts and soleus muscle using 14CO2 and 0.2 ml of benzethonium solution as described previously (20). Malonyl-CoA was measured by high-performance liquid chromatography as described previously (21).
###end p 26
###begin title 27
Analysis of physiological indicators.
###end title 27
###begin p 28
###xml 1 2 1 2 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 54 56 54 56 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B22">22</xref>
###xml 402 403 402 403 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 422 423 422 423 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 1062 1063 1046 1047 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B4">4</xref>
###xml 1064 1066 1048 1050 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B23">23</xref>
###xml 1066 1066 1050 1050 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B24"/>
###xml 1067 1069 1051 1053 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B25">25</xref>
###xml 96 100 <span type="species:ncbi:10090">mice</span>
###xml 251 255 <span type="species:ncbi:10090">mice</span>
###xml 323 327 <span type="species:ncbi:10090">mice</span>
###xml 490 494 <span type="species:ncbi:10090">mice</span>
O2 consumption was estimated as described previously (22). For indirect calorimetry, individual mice were placed in calorimetry chambers (Oxymax OPTO-M3 system; Columbus Instruments, Columbus, OH) and allowed to adapt for 48 h. During the first 24 h, mice had free access to food and water, and during the second 24 h, the mice had access to water only. Energy expenditure was calculated by measuring O2 consumption and CO2 production every 30 min for 24 h. For a cold-resistance test, DIO mice were exposed to 4degreesC ambient temperature for 12 h and rectal temperature was measured for 12 h. Blood samples were collected in heparinized tubes and separated by centrifugation and stored at -20degreesC for future use. Enzymatic colorimetry was used to quantify triglyceride, total cholesterol, free fatty acid, and glucose (Beckman Instruments, Palo Alto, CA). Plasma insulin (Linco Research, St. Charles, MO), TNFalpha (R&D System), adiponectin (Linco Research), resistin (KOMED), and leptin (Linco Research) were quantified by ELISA as described previously (4,23-25).
###end p 28
###begin title 29
DNA microarray and quantitative RT-PCR.
###end title 29
###begin p 30
###xml 601 603 596 598 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B26">26</xref>
###xml 95 99 <span type="species:ncbi:10090">mice</span>
###xml 328 333 <span type="species:ncbi:10090">mouse</span>
Microarray analysis was performed with pooled adipose, liver, or muscle tissue from adult male mice treated with vehicle or betaL for 4 weeks. Total RNA was prepared from homogenized tissues using Trizol reagent (Invitrogen, Carlsbad, CA). Probes for microarray analysis were prepared from 10 mug of total RNA and hybridized to mouse 430A GeneChips (Affymetrix, Santa Clara, CA). The hybridized arrays were scanned and raw data extracted using Microarray Analysis Suite 5.0 (Affymetrix). For quantitative PCR, cDNA was reverse transcribed from 1 mug of total RNA with Superscript II and oligo primer (26). The resulting cDNAs were amplified using a LightCycler FastStart DNA Master SYBR Green I kit and LightCycler according to the manufacturer's instructions (Roche Diagnostics, Indianapolis, IN). Expression data were normalized to beta-actin.
###end p 30
###begin title 31
Immunoblotting.
###end title 31
###begin p 32
Total proteins from liver, muscle (EDL and soleus), and indicated cells were extracted in RIPA lysis buffer (500 mmol/l Tris-HCl pH 7.4, 1 mmol/l EDTA, 150 mmol/l NaCl, 1% NP-40, 0.25% Na-deoxycholate, and 1 mmol/l phenylmethylsulfonl fluoride), and content was determined using the Bio-Rad dye binding microassay (Bio-Rad Laboratories, Inc, Hercules, CA). Protein (20 mug per lane) was electrophoresed on a sodium dodecyl sulfate SDS-polyacrylamide gel after boiling for 5 min in SDS sample buffer. Proteins were blotted onto Hybond enhanced luminescence membranes (Amersham Pharmacia Biotech, Arlington Heights, IL). After electroblotting, the membranes were blocked with TBS and Tween 20 (10 mmol/l Tris-HCl pH 7.4, 150 mmol/l NaCl, and 0.1% Tween 20) containing 5% nonfat dry milk and incubated with the primary antibody diluted in blocking buffer overnight at 4degreesC. Membranes were then washed, incubated with the appropriate second antibodies for 1 h at room temperature, and rewashed. Blotted proteins were detected by using enhanced chemiluminescence.
###end p 32
###begin p 33
###xml 125 126 123 124 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">t</italic>
###xml 194 195 192 193 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
Results are expressed as means +/- SD. Differences between groups were examined for statistical significance using Student's t test and ANOVA. The difference was considered to be significant if P < 0.05.
###end p 33
###begin title 34
RESULTS
###end title 34
###begin title 35
Enhanced cytosolic NADH oxidation by NQO1 stimulates cellular energy metabolism.
###end title 35
###begin p 36
###xml 239 240 236 237 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</italic>
###xml 512 513 503 504 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</italic>
###xml 692 693 680 681 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</italic>
###xml 751 752 739 740 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 835 837 823 825 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B15">15</xref>
###xml 917 918 902 903 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 982 988 964 970 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F1">Fig. 1</xref>
###xml 988 989 970 971 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</italic>
We screened natural compounds that induce NADH oxidation in the presence of NQO1. Interestingly, betaL and its structurally related compounds, tanshinone 2A and cryptotanshinone, rapidly induced NADH oxidation in vitro (supplemental Fig. 1A, available in an online appendix at ). In particular, betaL strongly decreased the fluorescence intensity of NADH in NQO1-expressing HepG2 cells but not in NQO1-deficient HEK293 cells, suggesting that NQO1 is required for betaL-induced NADH oxidation (supplemental Fig. 1B; available in the online appendix). Consistently, HEK293 cells transfected with wild-type NQO1 but not catalytically inactive NQO1 became responsive to betaL (supplemental Fig. 1B, available in the online appendix). We measured total NAD+ and NADH by the liquid chromatography-mass spectroscopy/mass spectroscopy method (15) in L6 muscle cells treated with different doses of betaL. As expected, the NAD+-to-NADH ratio was increased in L6 cells after betaL treatment (Fig. 1B). These results indicate that betaL induces NADH oxidation only in the presence of NQO1 activity.
###end p 36
###begin p 37
###xml 29 30 29 30 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 83 85 83 85 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B27">27</xref>
###xml 86 88 86 88 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B28">28</xref>
###xml 232 233 229 230 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B6">6</xref>
###xml 234 235 231 232 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B7">7</xref>
###xml 236 238 233 235 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B29">29</xref>
###xml 388 394 374 380 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F1">Fig. 1</xref>
###xml 394 395 380 381 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</italic>
###xml 419 420 405 406 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</italic>
###xml 572 578 555 561 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F1">Fig. 1</xref>
###xml 578 579 561 562 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</italic>
###xml 603 604 586 587 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</italic>
###xml 998 1001 972 975 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/&#8722;</sup>
###xml 1008 1014 982 988 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F1">Fig. 1</xref>
###xml 1014 1017 988 991 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">D&#8211;E</italic>
###xml 1123 1126 1094 1097 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/&#8722;</sup>
###xml 1146 1149 1117 1120 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 1156 1162 1127 1133 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F1">Fig. 1</xref>
###xml 1162 1165 1133 1136 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">D&#8211;E</italic>
###xml 1303 1304 1271 1272 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</italic>
###xml 749 753 <span type="species:ncbi:10090">mice</span>
###xml 778 783 <span type="species:ncbi:10090">mouse</span>
###xml 880 884 <span type="species:ncbi:10090">mice</span>
Because the intracellular NAD+-to-NADH ratio indicates the energy status of cells (27,28), betaL-induced NADH oxidation may stimulate the AMPK signaling pathway, a well-known energy sensing pathway activated under energy depletion (6,7,29). In fact, betaL treatment dramatically induced the activating phosphorylation in the catalytic subunit of AMPKalpha (AMPKalpha T172) within 30 min (Fig. 1C and supplemental Fig. 2A, available in the online appendix). Moreover, AMPK-dependent inhibitory phosphorylation of ACC (S79) was also strongly induced in betaL-treated cells (Fig. 1C and supplemental Fig. 2A, available in the online appendix). To examine whether betaL-induced AMPK activation requires NQO1 activity in vivo, we generated NQO1 knockout mice and injected betaL into mouse embryonic fibroblasts (MEFs) isolated from the heterozygous (+/-) and homozygous (-/-) knockout mice. betaL-induced phosphorylations of AMPK and ACC were not observed in NQO1-deficient MEFs but were observed in NQO+/- MEFs (Fig. 1D-E). Consistent with these immunoblot results, betaL treatment modulated AMPK and ACC activities only in NQO+/- MEFs but not in NQO-/- MEFs (Fig. 1D-E). Furthermore, NQO1-specific inhibitors, dicoumarol and ES936, completely blocked betaL-induced AMPK phosphorylation (supplemental Fig. 2B, available in the online appendix). These results collectively indicate that betaL induces AMPK activation specifically by NQO1.
###end p 37
###begin p 38
###xml 87 89 87 89 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B30">30</xref>
###xml 90 92 90 92 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B31">31</xref>
###xml 320 326 317 323 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F1">Fig. 1</xref>
###xml 326 329 323 326 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">F&#8211;G</italic>
###xml 393 395 390 392 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">14</sup>
###xml 472 478 466 472 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F1">Fig. 1</xref>
###xml 478 479 472 473 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">H</italic>
Because AMPK activation and concomitant ACC inhibition stimulate fatty acid oxidation (30,31), we measured the activities of two representative metabolic enzymes regulating mitochondrial fatty acid oxidation. Intriguingly, the activities of CPT and 3-HAD were significantly increased in betaL-treated L6 myoblast cells (Fig. 1F-G). Consistently, mitochondrial fatty acid oxidation measured by 14C-palmitoyl-CoA oxidation was substantially elevated in betaL-treated cells (Fig. 1H). These results suggest that betaL-induced NADH oxidation activates mitochondrial fuel metabolism by stimulating the AMPK signaling pathway.
###end p 38
###begin title 39
Pharmacological NADH oxidation stimulates activation of AMP-activated protein kinase and fatty acid oxidation in vivo.
###end title 39
###begin p 40
###xml 173 174 164 165 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 215 221 206 212 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F2">Fig. 2</xref>
###xml 221 222 212 213 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</italic>
###xml 387 393 375 381 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F2">Fig. 2</xref>
###xml 393 396 381 384 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B&#8211;E</italic>
###xml 651 653 633 635 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B32">32</xref>
###xml 654 656 636 638 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B33">33</xref>
###xml 680 686 662 668 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F2">Fig. 2</xref>
###xml 686 689 668 671 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">F&#8211;G</italic>
###xml 824 830 803 809 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F2">Fig. 2</xref>
###xml 830 833 809 812 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">H&#8211;I</italic>
###xml 922 928 898 904 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F2">Fig. 2</xref>
###xml 928 929 904 905 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">J</italic>
###xml 96 100 <span type="species:ncbi:10090">mice</span>
###xml 209 213 <span type="species:ncbi:10090">mice</span>
###xml 381 385 <span type="species:ncbi:10090">mice</span>
###xml 535 539 <span type="species:ncbi:10090">mice</span>
###xml 774 778 <span type="species:ncbi:10090">mice</span>
###xml 818 822 <span type="species:ncbi:10090">mice</span>
###xml 916 920 <span type="species:ncbi:10090">mice</span>
To investigate the in vivo effects of betaL, we examined betaL-induced metabolic changes in DIO mice. Consistent with the cell data, betaL treatment highly increased the NAD+-to-NADH ratio in the liver of DIO mice (Fig. 2A). Moreover, betaL treatment substantially increased the phosphorylations of AMPK and ACC and the activity of AMPK in the liver, EDL, and soleus muscle of DIO mice (Fig. 2B-E). We also monitored several enzymatic activities involved in mitochondrial fatty acid oxidation in the soleus muscle of betaL-treated DIO mice. betaL treatment significantly reduced the activity of ACC and the level of its metabolic product malonyl-CoA (32,33) in the soleus muscle (Fig. 2F-G). In contrast, the activities of CPT and HAD were highly increased in betaL-treated mice compared with those of vehicle-treated mice (Fig. 2H-I). The rate of mitochondrial fatty acid oxidation was much higher in betaL-treated mice (Fig. 2J). These data indicate that increased NADH oxidation by betaL treatment stimulates the AMPK signaling pathway and mitochondrial fatty acid oxidation in vivo.
###end p 40
###begin p 41
###xml 104 105 101 102 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</italic>
###xml 110 111 107 108 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 203 204 200 201 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 210 219 207 216 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">open bars</italic>
###xml 239 240 233 234 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 246 257 240 251 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">closed bars</italic>
###xml 284 285 278 279 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 295 298 289 292 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B&#8211;D</italic>
###xml 397 398 388 389 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</italic>
###xml 406 407 397 398 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</italic>
###xml 422 423 413 414 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">D</italic>
###xml 467 468 458 459 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 493 494 481 482 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 556 557 541 542 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</italic>
###xml 593 594 578 579 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</italic>
###xml 616 617 601 602 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">D</italic>
###xml 686 688 671 673 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E:</italic>
###xml 818 819 800 801 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 840 843 822 825 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">F&#8211;G</italic>
###xml 878 879 860 861 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">F</italic>
###xml 907 908 889 890 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">G</italic>
###xml 997 998 976 977 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 1019 1022 998 1001 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">H&#8211;J</italic>
###xml 1143 1144 1119 1120 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">H</italic>
###xml 1165 1166 1141 1142 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">I</italic>
###xml 1172 1174 1148 1150 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">14</sup>
###xml 1200 1201 1176 1177 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">J</italic>
###xml 1251 1252 1224 1225 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 1319 1320 1292 1293 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 1331 1332 1304 1305 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 162 166 <span type="species:ncbi:10090">mice</span>
###xml 430 434 <span type="species:ncbi:10090">mice</span>
###xml 759 763 <span type="species:ncbi:10090">mice</span>
###xml 938 942 <span type="species:ncbi:10090">mice</span>
###xml 1080 1084 <span type="species:ncbi:10090">mice</span>
###xml 1245 1249 <span type="species:ncbi:10090">mice</span>
###xml 1273 1277 <span type="species:ncbi:10090">Mice</span>
betaL activates AMP-activated protein kinase (AMPK) signaling pathway and fatty acid oxidation in vivo. A: NAD+-to-NADH ratio was calculated in the liver of male mice treated intravenously with vehicle (n = 5; open bars) or 5 mg/kg betaL (n = 5; closed bars) for the indicated time (*P < 0.05). B-D: Effects of betaL on phosphorylations of AMPK and acetyl-CoA carboxylase (ACC) in vivo for liver (B), EDL (C), and soleus (D). DIO mice were dosed orally with vehicle (n = 3) or 50 mg/kg betaL (n = 3). After treatment of betaL for 2 h, extracts from liver (B), extensor digitorum longus (EDL) (C), and soleus muscle (D) were immunoblotted with antibodies against the indicated proteins. E: Comparison of the AMPK activity in the three indicated tissues of DIO mice dosed orally with vesicle and 50 mg/kg betaL for 2 h (n = 5, respectively). F-G: Comparisons of the ACC activity (F) and malonyl-CoA quantity (G) in the soleus muscle of DIO mice dosed orally with vesicle and 50 mg/kg betaL for 2 h (n = 5, respectively). H-J: betaL stimulates mitochondrial energy metabolism in DIO mice. Comparisons of the carnitine palmitoyltransferase (CPT) (H), 3-HAD activities (I), or 14C-palmityl-CoA oxidation (J) in vehicle and 50 mg/kg betaL-treated DIO mice (n = 5, respectively). Mice used for all the experiments were male (*P < 0.05; **P < 0.005).
###end p 41
###begin title 42
###xml 79 84 76 81 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ob/ob</italic>
###xml 70 74 <span type="species:ncbi:10090">mice</span>
###xml 85 89 <span type="species:ncbi:10090">mice</span>
betaL reverses obesity and related phenotypes in diet-induced obesity mice and ob/ob mice.
###end title 42
###begin p 43
###xml 167 173 161 167 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F3">Fig. 3</xref>
###xml 351 357 342 348 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F3">Fig. 3</xref>
###xml 357 358 348 349 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</italic>
###xml 501 507 489 495 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F3">Fig. 3</xref>
###xml 507 508 495 496 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</italic>
###xml 628 634 613 619 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F3">Fig. 3</xref>
###xml 634 637 619 622 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A&#8211;B</italic>
###xml 820 826 799 805 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F3">Fig. 3</xref>
###xml 826 827 805 806 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</italic>
###xml 848 849 827 828 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 875 876 854 855 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 1281 1287 1234 1240 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F3">Fig. 3</xref>
###xml 1287 1288 1240 1241 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</italic>
###xml 138 142 <span type="species:ncbi:10090">mice</span>
###xml 244 248 <span type="species:ncbi:10090">mice</span>
###xml 326 330 <span type="species:ncbi:10090">mice</span>
###xml 409 413 <span type="species:ncbi:10090">mice</span>
###xml 532 536 <span type="species:ncbi:10090">mice</span>
###xml 1399 1403 <span type="species:ncbi:10090">mice</span>
To examine whether betaL-induced NADH oxidation has a therapeutic potential in treating metabolic syndrome, we systematically treated DIO mice with betaL for 8 weeks (Fig. 3, supplemental Fig. 3). Surprisingly, the body weight of betaL-treated mice continuously decreased throughout the treatment, whereas that of the control mice slightly increased (Fig. 3A). Interestingly, the food intake of betaL-treated mice decreased during the first 2 weeks of treatment and then returned to the normal state (Fig. 3B) because betaL-treated mice exhibited progressive weight loss even after returning to the normal state of food intake (Fig. 3A-B). To observe the role of decreased food intake in the early phase of betaL administration, we compared the body weight of the betaL-treated group with that of the pair-fed group. In Fig. 3C, the treated group (n = 8) and pair-fed group (n = 8) showed 24.9 +/- 7.36% and -3.4 +/- 7.86% weight loss compared with the baseline weight. A comparison of the weights of the treated and pair-fed groups to those of the vehicle group showed that the betaL-treated and pair-fed groups had weight losses of 33.6 +/- 5.78% and 10.5 +/- 3.00%, respectively; thus, approximately23% of total weight loss can be attributed to the peripheral actions of betaL (Fig. 3C, supplemental Fig. 3). These findings suggest that a major factor governing body weight loss in betaL-treated mice is likely to be increased energy expenditure rather than decreased food intake.
###end p 43
###begin p 44
###xml 64 67 61 64 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A&#8211;B</italic>
###xml 87 88 84 85 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</italic>
###xml 136 137 133 134 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</italic>
###xml 165 166 157 158 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 204 205 186 187 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 221 222 200 201 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">l</sc>
###xml 247 248 214 215 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 321 323 288 290 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;1</sup>
###xml 329 331 296 298 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;1</sup>
###xml 351 352 315 316 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</italic>
###xml 396 397 355 356 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 427 428 376 377 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 449 451 398 400 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;1</sup>
###xml 457 459 406 408 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;1</sup>
###xml 490 491 424 425 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 569 570 500 501 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 581 582 512 513 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 593 594 524 525 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">D</italic>
###xml 631 642 562 573 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">upper panel</italic>
###xml 660 671 591 602 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">lower panel</italic>
###xml 772 774 703 705 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;1</sup>
###xml 780 782 711 713 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;1</sup>
###xml 865 866 793 794 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E</italic>
###xml 969 973 897 901 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">left</italic>
###xml 989 991 917 919 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;1</sup>
###xml 997 999 925 927 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;1</sup>
###xml 1007 1012 932 937 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">right</italic>
###xml 1125 1126 1050 1051 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">F</italic>
###xml 1148 1151 1073 1076 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">red</italic>
###xml 1202 1207 1127 1132 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">upper</italic>
###xml 1222 1224 1147 1149 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;1</sup>
###xml 1230 1232 1155 1157 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;1</sup>
###xml 1240 1245 1162 1167 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">lower</italic>
###xml 1345 1346 1267 1268 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 1357 1358 1279 1280 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 58 62 <span type="species:ncbi:10090">mice</span>
###xml 704 708 <span type="species:ncbi:10090">mice</span>
###xml 721 725 <span type="species:ncbi:10090">mice</span>
###xml 807 811 <span type="species:ncbi:10090">mice</span>
###xml 942 946 <span type="species:ncbi:10090">mice</span>
###xml 1175 1179 <span type="species:ncbi:10090">mice</span>
###xml 1299 1303 <span type="species:ncbi:10090">Mice</span>
betaL treatment ameliorates the metabolic symptoms of DIO mice. A-B: The body weights (A) and the ratios of food intake to body weight (B) of the untreated (square; n = 30), vehicle-treated (triangle up; n = 42), and betal-treated (triangle down; n = 48) groups were monitored during the oral administration of 50 mg . kg-1 . day-1 betaL for 8 weeks. C: The body weight of the untreated (square; n = 6), pair-fed (triangle up; n = 8), and 50 mg . kg-1 . day-1 betaL-treated (triangle down; n = 8) groups, were monitored for 8 weeks after oral administration of betaL (*P < 0.05; **P < 0.005). D: Representative MRI of the coronal (upper panel) and transverse (lower panel) sections in the four indicated mice groups. DIO mice were orally administered vehicle or 50 mg . kg-1 . day-1 betaL for 8 weeks. Lean mice were used as control for a normal fat concentration. E: The sizes of lipid droplets in gonadal fat (GF) were compared between DIO mice treated with vehicle (left) and 50 mg . kg-1 . day-1 betaL (right) for 4 weeks. Immunostaining with anti-perilipin antibody (red) was used to measure the size of lipid droplets. F: Oil red O staining (red) in the liver from DIO mice treated with vehicle (upper) or 50 mg . kg-1 . day-1 betaL (lower) for 4 weeks was used to evaluate hepatic steatosis. Mice used for all the experiments were male (*P < 0.05; **P < 0.005). (A high-quality digital representation of this figure is available in the online issue.)
###end p 44
###begin p 45
###xml 184 190 181 187 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F3">Fig. 3</xref>
###xml 190 191 187 188 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">D</italic>
###xml 700 707 688 695 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="T1">Table 1</xref>
###xml 872 878 857 863 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F3">Fig. 3</xref>
###xml 878 879 863 864 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E</italic>
###xml 1009 1015 991 997 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F3">Fig. 3</xref>
###xml 1015 1016 997 998 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">F</italic>
###xml 1180 1185 1159 1164 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ob/ob</italic>
###xml 1192 1198 1171 1177 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F4">Fig. 4</xref>
###xml 1198 1201 1177 1180 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A&#8211;D</italic>
###xml 107 111 <span type="species:ncbi:10090">mice</span>
###xml 294 298 <span type="species:ncbi:10090">mice</span>
###xml 533 537 <span type="species:ncbi:10090">mice</span>
###xml 694 698 <span type="species:ncbi:10090">mice</span>
###xml 866 870 <span type="species:ncbi:10090">mice</span>
###xml 1003 1007 <span type="species:ncbi:10090">mice</span>
###xml 1186 1190 <span type="species:ncbi:10090">mice</span>
###xml 1323 1327 <span type="species:ncbi:10090">mice</span>
###xml 1388 1392 <span type="species:ncbi:10118|species:ncbi:10116">rats</span>
Consistent with the decreased body weight, MRI of the coronal and transverse sections of betaL-treated DIO mice showed dramatic decreases in subcutaneous and visceral adipose tissues (Fig. 3D). Moreover, the weights of subcutaneous, mesenteric, perirenal, and gonadal fats in betaL-treated DIO mice were considerably decreased (supplemental Fig. 4), indicating that their body weight loss is the result of the reduced adipose tissues. After analyzing various indicators of glucose and fat metabolism in the sera of betaL-treated DIO mice, we found overall decreased amounts of triglyceride, cholesterol, free fatty acid, glucose, insulin, adiponectin, resistin, and leptin in betaL-treated DIO mice (Table 1). Notably, the adipocyte marker perilipin staining revealed that the size of lipid droplets in the epididymal fat cells was much smaller in betaL-treated DIO mice (Fig. 3E). Moreover, oil red O staining in the liver showed that betaL treatment considerably suppressed the liver steatosis in DIO mice (Fig. 3F). All these dramatic metabolic changes, including reduced body weight and adipocyte size, and decreased hepatic steatosis were similarly observed in betaL-treated ob/ob mice (Fig. 4A-D). Consistently, betaL treatment resulted in enhanced glucose disposal rates and improved insulin sensitivity in both DIO mice and Otsuka Long Evans Tokushima fatty type 2 diabetic model rats (supplemental Fig. 5).We conclude that betaL treatment can alleviate the key symptoms of metabolic syndrome in the rodent models with obesity and diabetes.
###end p 45
###begin p 46
###xml 24 28 <span type="species:ncbi:10090">mice</span>
Metabolic parameters in mice treated with vehicle or betaL
###end p 46
###begin p 47
###xml 63 64 61 62 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 80 81 75 76 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 137 138 132 133 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
Data are means +/- SD. After oral administration with vehicle (n = 5) or betaL (n = 6) for 4 weeks, metabolic parameters were analyzed. *P < 0.05,
###end p 47
###begin p 48
###xml 2 3 2 3 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
**P < 0.005 for the betaL-treated group versus the vehicle control group.
###end p 48
###begin p 49
###xml 54 59 51 56 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ob/ob</italic>
###xml 66 67 63 64 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</italic>
###xml 72 73 69 70 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</italic>
###xml 92 93 89 90 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</italic>
###xml 140 141 137 138 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</italic>
###xml 169 170 161 162 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 207 208 189 190 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 230 232 212 214 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;1</sup>
###xml 238 240 220 222 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;1</sup>
###xml 271 272 238 239 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 350 351 314 315 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 362 363 326 327 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 374 375 338 339 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</italic>
###xml 442 444 406 408 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;1</sup>
###xml 450 452 414 416 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;1</sup>
###xml 467 472 428 433 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ob/ob</italic>
###xml 506 507 467 468 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">D</italic>
###xml 539 550 500 511 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">upper panel</italic>
###xml 573 584 534 545 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">lower panel</italic>
###xml 589 594 550 555 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ob/ob</italic>
###xml 622 632 583 593 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">left panel</italic>
###xml 648 650 609 611 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;1</sup>
###xml 656 658 617 619 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;1</sup>
###xml 666 677 624 635 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">right panel</italic>
###xml 732 743 690 701 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">upper panel</italic>
###xml 774 785 732 743 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">lower panel</italic>
###xml 60 64 <span type="species:ncbi:10090">mice</span>
###xml 473 477 <span type="species:ncbi:10090">mice</span>
###xml 595 599 <span type="species:ncbi:10090">mice</span>
The effects of betaL on various metabolic symptoms in ob/ob mice. A and B: The body weight (A) and the ratio of food intake to body weight (B) of the untreated (square; n = 4), vehicle-treated (triangle up; n = 8), and 200 mg . kg-1 . day-1 betaL-treated (triangle down; n = 8) groups, were monitored for 8 weeks after oral administration of betaL (*P < 0.05; **P < 0.005). C: The photographic images of lean, vehicle-treated, and 200 mg . kg-1 . day-1 betaL-treated ob/ob mice after 8 weeks of treatment. D: Tissue sections of the liver (upper panel) and gonadal fat (GF, lower panel) of ob/ob mice treated with vehicle (left panel) or 200 mg . kg-1 . day-1 betaL (right panel) for 8 weeks were stained with hematoxylin and eosin (upper panel) and anti-perilipin antibody (lower panel), respectively. (A high-quality digital representation of this figure is available in the online issue.)
###end p 49
###begin title 50
Pharmacological NADH oxidation modulates expression of genes involved in metabolism and mitochondrial functions.
###end title 50
###begin p 51
###xml 384 391 375 382 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="T2">Table 2</xref>
###xml 536 538 520 522 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B34">34</xref>
###xml 539 541 523 525 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B35">35</xref>
###xml 803 804 784 785 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B5">5</xref>
###xml 805 807 786 788 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B36">36</xref>
###xml 808 810 789 791 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B37">37</xref>
###xml 1127 1129 1098 1100 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B38">38</xref>
###xml 196 200 <span type="species:ncbi:10090">mice</span>
###xml 296 300 <span type="species:ncbi:10090">mice</span>
###xml 575 579 <span type="species:ncbi:10090">mice</span>
###xml 697 701 <span type="species:ncbi:10090">mice</span>
###xml 869 873 <span type="species:ncbi:10090">mice</span>
###xml 1014 1018 <span type="species:ncbi:10090">mice</span>
###xml 1172 1176 <span type="species:ncbi:10090">mice</span>
To further understand the underlying mechanisms of betaL-induced metabolic improvements, we performed genomewide microarray analyses in the liver, muscle, and adipose tissues of betaL-treated DIO mice. Genes involved in metabolism and mitochondrial functions were differentially expressed in DIO mice exposed to betaL, and quantitative RT-PCR experiments also verified these results (Table 2). For example, betaL treatment strongly induced PGC-1alpha and nuclear respiratory factor-1, the master regulators of mitochondrial biogenesis (34,35), in the liver and muscle of DIO mice. In addition, mitochondrial metabolic genes (COX4 and COX7) were also upregulated in the muscle of betaL-treated DIO mice. Interestingly, Sirt1 and Sirt3, which are known to be activated in response to calorie restriction (5,36,37), were also highly induced in the muscle of betaL-treated mice. Moreover, genes related to lipolysis (LPL and ATGL) and glucose uptake (GLUT4) were upregulated in the adipose tissue of betaL-treated DIO mice. However, fatty acid synthase and PPARgamma, which play key roles in adipogenesis and fatty acid synthesis (38), were downregulated in betaL-treated DIO mice. These results strongly suggest that betaL-induced NADH oxidation stimulates mitochondrial biogenesis and functions and also enhances energy metabolism by controlling global gene expression related to cellular metabolism.
###end p 51
###begin p 52
Expression of genes related to energy metabolism and mitochondrial functions in the liver, muscle, and white adipose tissue
###end p 52
###begin p 53
###xml 63 64 61 62 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 80 81 75 76 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 295 296 287 288 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
Data are means +/- SD. After oral administration with vehicle (n = 5) or betaL (n = 6) for 4 weeks, relative mRNA levels in the indicated tissues were analyzed by quantitative RT-PCR. The values indicate relative mRNA levels of betaL-treated groups compared to those of vehicle control groups. *P < 0.05,
###end p 53
###begin p 54
###xml 2 3 2 3 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
**P < 0.005 for the betaL-treated group versus the vehicle control group.
###end p 54
###begin title 55
Long-term pharmacological NADH oxidation stimulates mitochondrial biogenesis and energy expenditure.
###end title 55
###begin p 56
###xml 104 106 101 103 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B34">34</xref>
###xml 107 109 104 106 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B39">39</xref>
###xml 110 112 107 109 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B40">40</xref>
###xml 349 355 343 349 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F5">Fig. 5</xref>
###xml 355 358 349 352 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A&#8211;B</italic>
###xml 532 538 523 529 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F5">Fig. 5</xref>
###xml 538 541 529 532 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A&#8211;B</italic>
###xml 830 836 815 821 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F5">Fig. 5</xref>
###xml 836 837 821 822 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</italic>
###xml 1017 1023 999 1005 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F5">Fig. 5</xref>
###xml 1023 1024 1005 1006 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">D</italic>
###xml 210 214 <span type="species:ncbi:10090">mice</span>
###xml 272 276 <span type="species:ncbi:10090">mice</span>
###xml 374 378 <span type="species:ncbi:10090">mice</span>
###xml 628 632 <span type="species:ncbi:10090">mice</span>
###xml 1011 1015 <span type="species:ncbi:10090">mice</span>
Because several genes affected by betaL treatment take part in mitochondrial remodeling and biogenesis (34,39,40), we examined the physiological and ultrastructural changes of mitochondria in betaL-treated DIO mice. As a result, mitochondria in the liver of untreated DIO mice appeared to be swollen, distorted, and deficient in cristae and matrix (Fig. 5A-B). However, DIO mice treated with betaL for 8 weeks showed an increased number of mitochondria with normal morphologies such as well-organized cristae and matrix structures (Fig. 5A-B). Furthermore, the mitochondria collected from the soleus muscle in betaL-treated DIO mice exhibited higher levels of mitochondrial DNA and complex II subunit expression compared with those in untreated controls, suggesting that betaL treatment actively induced mitochondrial biogenesis (Fig. 5C). Consistently, the number of fibers in the soleus muscle that showed strong ATPase staining intensity and intermyofibrillar mitochondria was increased in betaL-treated DIO mice (Fig. 5D).
###end p 56
###begin p 57
###xml 112 113 109 110 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</italic>
###xml 118 119 115 116 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</italic>
###xml 176 177 173 174 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</italic>
###xml 198 199 195 196 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</italic>
###xml 247 249 244 246 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;1</sup>
###xml 255 257 252 254 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;1</sup>
###xml 337 338 331 332 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</italic>
###xml 388 399 382 393 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">upper panel</italic>
###xml 474 485 468 479 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">lower panel</italic>
###xml 557 558 551 552 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 577 579 571 573 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;1</sup>
###xml 585 587 579 581 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;1</sup>
###xml 595 596 586 587 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 646 647 633 634 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">D</italic>
###xml 679 690 666 677 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">pale purple</italic>
###xml 786 790 773 777 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">left</italic>
###xml 803 808 787 792 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">right</italic>
###xml 811 812 795 796 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E</italic>
###xml 817 818 801 802 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">F</italic>
###xml 840 841 824 825 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">V</italic>
###xml 841 842 825 826 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">o</sc>
###xml 842 843 826 827 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 846 847 830 831 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E</italic>
###xml 870 871 854 855 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">F</italic>
###xml 934 935 913 914 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 954 956 933 935 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;1</sup>
###xml 962 964 941 943 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;1</sup>
###xml 987 988 951 952 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 1007 1008 971 972 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">G</italic>
###xml 1142 1143 1103 1104 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 1154 1155 1115 1116 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 208 212 <span type="species:ncbi:10090">mice</span>
###xml 530 534 <span type="species:ncbi:10090">mice</span>
###xml 759 763 <span type="species:ncbi:10090">mice</span>
###xml 899 903 <span type="species:ncbi:10090">mice</span>
###xml 1059 1063 <span type="species:ncbi:10090">mice</span>
###xml 1096 1100 <span type="species:ncbi:10090">Mice</span>
Long-term betaL treatment stimulates mitochondrial remodelling and biogenesis and increases energy expenditure. A and B: Transmission electron microscopic images of the liver (A) and soleus muscle (B) of DIO mice treated with vehicle or 50 mg . kg-1 . day-1 betaL for 8 weeks. N, nucleus; L, lipid droplets; C, cytosol; M, mitochondria. C: Immunoblot analysis against complex II subunit (upper panel) and quantitative RT-PCR analysis for mitochondrial DNA (mtDNA) contents (lower panel) were performed in the soleus muscle of DIO mice treated with vehicle (n = 5) or 50 mg . kg-1 . day-1 betaL (n = 5). alpha-Tubulin was used as loading control. D: pH-sensitive ATPase staining (pale purple) of histological sections was performed in the soleus muscle of DIO mice treated with vehicle (left) and betaL (right). E and F: Oxygen consumption (Vo2) (E) and cold resistance (F) were compared between DIO mice treated with vehicle (square; n = 5) or 50 mg . kg-1 . day-1 betaL (triangle down; n = 5) for 8 weeks. G: Comparison of the energy expenditure between DIO mice treated with vehicle and betaL. Mice used for all the experiments were male (*P < 0.05; **P < 0.005). (A high-quality digital representation of this figure is available in the online issue.)
###end p 57
###begin p 58
###xml 232 233 229 230 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">V</italic>
###xml 233 234 230 231 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">o</sc>
###xml 234 235 231 232 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 319 325 313 319 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F5">Fig. 5</xref>
###xml 325 326 319 320 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E</italic>
###xml 438 439 429 430 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 475 476 466 467 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">V</italic>
###xml 476 477 467 468 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">o</sc>
###xml 477 478 468 469 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 736 737 721 722 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">V</italic>
###xml 737 738 722 723 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">o</sc>
###xml 738 739 723 724 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 840 846 822 828 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F5">Fig. 5</xref>
###xml 846 847 828 829 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">F</italic>
###xml 940 946 919 925 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F5">Fig. 5</xref>
###xml 946 947 925 926 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">G</italic>
###xml 100 104 <span type="species:ncbi:10090">mice</span>
###xml 313 317 <span type="species:ncbi:10090">mice</span>
###xml 412 416 <span type="species:ncbi:10090">mice</span>
###xml 432 436 <span type="species:ncbi:10090">mice</span>
###xml 772 776 <span type="species:ncbi:10090">mice</span>
###xml 834 838 <span type="species:ncbi:10090">mice</span>
###xml 934 938 <span type="species:ncbi:10090">mice</span>
###xml 1149 1153 <span type="species:ncbi:10090">mice</span>
To further characterize the physiological effects of mitochondrial restoration in betaL-treated DIO mice, we measured two metabolic indices: respiratory oxygen consumption and cold resistance. The quantity of resting oxygen uptake (Vo2) was markedly increased after adjusting for body weight in betaL-treated DIO mice (Fig. 5E), whereas the ratio of night respiratory exchange was decreased (0.77, betaL-treated mice; 0.82, control mice; P < 0.005, data not shown). However, Vo2 that had not been adjusted for body weight showed no statistical significance between control and betaL-treated groups. Thus, adipose tissue mass, which is profoundly decreased by betaL treatment, may be an important denominator for the analysis of resting Vo2. In addition, betaL-treated DIO mice displayed much stronger cold resistance than the control mice (Fig. 5F). More importantly, betaL treatment significantly increased energy expenditure of DIO mice (Fig. 5G). Overall, these results propose that increases in mitochondrial integrity, oxygen consumption, and energy expenditure are the underlying mechanisms of betaL in assuaging the metabolic symptoms of DIO mice.
###end p 58
###begin title 59
DISCUSSION
###end title 59
###begin p 60
###xml 3 4 3 4 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 80 82 80 82 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B11">11</xref>
###xml 118 119 118 119 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 214 215 214 215 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 362 364 362 364 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B41">41</xref>
###xml 426 427 426 427 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 480 481 480 481 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 497 498 497 498 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B5">5</xref>
###xml 545 546 545 546 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 668 670 668 670 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B28">28</xref>
###xml 671 673 671 673 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B42">42</xref>
###xml 713 714 713 714 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 783 785 783 785 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B10">10</xref>
###xml 856 857 856 857 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 343 348 <span type="species:ncbi:4932">yeast</span>
###xml 367 372 <span type="species:ncbi:4932">Yeast</span>
NAD+ and its derivatives are classic metabolites involved in energy metabolism (11). Recent evidence suggests that NAD+ is a central regulator in cellular energy metabolism. Moreover, the importance of cellular NAD+ levels has been highlighted by the discovery of SIR2-related proteins (sirtuins) that mediate calorie-restriction responses in yeast and mammals (41). Yeast Sir2 and a mammalian ortholog sirtuin, Sirt1, are NAD+-dependent deacetylases that are regulated by the NAD+-to-NADH ratio (5). Accumulating evidence has suggested that NAD+-to-NADH ratios are altered in various pathological conditions such as neurodegeneration, diabetes, and oxidative stress (28,42). The pharmacological activation of NAD+-dependent SirT1 compensates for the effects of a high-calorie diet (10). Based on these observations, pharmacological induction of higher NAD+-to-NADH would be expected to ameliorate the metabolic syndrome.
###end p 60
###begin p 61
###xml 223 225 220 222 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B14">14</xref>
###xml 292 293 286 287 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 882 884 873 875 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B43">43</xref>
###xml 1171 1172 1162 1163 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 897 902 <span type="species:ncbi:9606">human</span>
NQO1 is a flavoenzyme that uses NAD(P)H as an electron donor to catalyze the reduction of substrates. Previous studies and our data suggest that betaL is a specific and high-affinity substrate of NQO1 in vitro and in vivo (14). betaL would therefore have the propensity to induce a higher NAD+-to-NADH ratio. The expression of NQO1, a target of betaL, is highly upregulated in liver, muscle, and fat tissues, which are important for the regulation of whole-body energy metabolism and insulin sensitivity (supplemental Fig. 6). The promoter of the NQO1 gene has an antioxidant response element that serves as the binding motif for the factor Nrf2, which is activated by reactive oxygen species (ROS) stimuli. The increased ROS stimulation in metabolically active tissues under obesity and diabetic conditions may activate Nrf2 and NQO1 gene expression. Consistently, Palming et al. (43) found that human adipocytes have high NQO1 expression and that NQO1 expression levels were positively correlated with adiposity, glucose tolerance, and markers of liver dysfunction. Taken together, NQO1 would appear to be a useful pharmacological target for the induction of higher NAD+-to-NADH ratios in obesity and diabetes models.
###end p 61
###begin p 62
###xml 433 435 424 426 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B10">10</xref>
###xml 436 438 427 429 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B36">36</xref>
###xml 439 441 430 432 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B44">44</xref>
###xml 552 554 543 545 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B45">45</xref>
###xml 555 557 546 548 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B46">46</xref>
###xml 916 917 901 902 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</italic>
We have shown that the enhanced NADH oxidation induced by betaL in NQO1-present cells increases phosphorylation and activation of AMPK. The reduced cytosolic NADH levels induced by betaL treatment may disturb the proper distribution of NADH reducing equivalents in mitochondrial complexes for energy production, suggesting that betaL may transiently increase AMP levels and activate AMPK to compensate for cellular energy depletion (10,36,44). Two upstream kinases, LKB1 and CaMKK, are involved in the phosphorylation of the catalytic subunit of AMPK (45,46). We tested the effects of betaL on AMPK phosphorylation in LKB1-deficient MEFs. AMPK phosphorylation was only observed at very early time points (30 s to 5 min) after treatment with betaL in LKB1-deficient cells (data not shown). This pattern of AMPK activation is quite different from that observed in cells with normal LKB1 expression (supplemental Fig. 2A), in which betaL resulted in prolonged AMPK phosphorylation. The CaMKK inhibitor (STO609) completely abolished the early phase of AMPK phosphorylation (data not shown). These findings strongly suggest that both LKB1 and CaMKK are required for full activation of AMPK under betaL-induced AMPK phosphorylation conditions. Activation of AMPK led to increased fatty acid oxidation by inactivating ACC phosphorylation. Consistently, betaL-mediated AMPK activation induces ACC phosphorylation and activation of CPT and HAD, resulting in beneficial fatty acid oxidation. Taken together, these findings suggest that pharmacological stimulation of NADH oxidation leads to increased mitochondrial fatty acid oxidation.
###end p 62
###begin p 63
###xml 174 180 171 177 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F3">Fig. 3</xref>
###xml 180 181 177 178 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</italic>
###xml 527 531 <span type="species:ncbi:10090">mice</span>
We additionally examined whether betaL-induced NADH oxidation could be used as a therapy for treating obesity, a major component of metabolic syndrome. Pair-feeding studies (Fig. 3C, supplemental Fig. 3) clearly demonstrated that loss of weight induced by betaL is mediated by both central and peripheral actions. Although a decrease of food intake after betaL treatment was noted in the early phase of treatment, food intake recovered with continued betaL administration. We found that intracranial administration of betaL in mice resulted in a dramatic decrease in feeding behavior (data not shown); however, it is unclear which mechanism in the hypothalamus mediates the betaL-induced decrease in food intake. Long-term weight loss induced by betaL is mainly the result of the peripheral action of betaL and its weight-reducing effect, which are accompanied by a smaller fat mass; lower fatty infiltration in the liver; decreased levels of plasma insulin, triglyceride, and glucose; and increased glucose disposal rates after insulin treatment. These results suggest that the increased NADH oxidation induced by betaL could lead to an amelioration of key components of metabolic syndrome in rodent models with obesity and diabetes.
###end p 63
###begin p 64
###xml 56 61 56 61 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ob/ob</italic>
###xml 403 405 400 402 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B47">47</xref>
###xml 406 408 403 405 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B48">48</xref>
###xml 973 974 952 953 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">V</italic>
###xml 974 975 953 954 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">o</sc>
###xml 975 976 954 955 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 1263 1264 1236 1237 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">V</italic>
###xml 1264 1265 1237 1238 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">o</sc>
###xml 1265 1266 1238 1239 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 1372 1373 1342 1343 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">V</italic>
###xml 1373 1374 1343 1344 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">o</sc>
###xml 1374 1375 1344 1345 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 62 66 <span type="species:ncbi:10090">mice</span>
###xml 955 959 <span type="species:ncbi:10090">mice</span>
The reversal of obesity and other phenotypes of DIO and ob/ob mice by betaL is associated with the normalization of disorganized mitochondrial ultrastructure and increased numbers of mitochondria. Mitochondrial dysfunctions are frequently associated with obesity and diabetes, and improvements in obesity and glucose tolerance are associated with enhanced mitochondrial oxphos functions and biogenesis (47,48). En examination of the gene expression patterns after betaL treatment showed increased expression of PGC-1alpha and SirT family genes in liver, muscle, and adipose tissues. Prolonged AMPK activation is known to increase PGC-1alpha expression, SirT1 activity, and mitochondrial biogenesis. Taken together, it is plausible that AMPK activation by betaL induces PGC-1alpha, a master regulator of mitochondrial biogenesis, and Sirt1, a mediator of calorie-restriction effects, which promote higher mitochondrial biogenesis and energy expenditure in mice. The resting Vo2 was found to be higher in the betaL-treated group than in the vehicle group after adjusting for body weight. However, this finding does not necessarily indicate that betaL treatment increases resting metabolic rate because changes of body weight, including fat mass, may affect resting Vo2. To find the effects of betaL treatment on metabolic rate, additional analysis of submaximal and maximal Vo2 with or without adjustments for body composition will be required. The consequences of long-term physiological adaptations on enhanced NADH oxidation after betaL treatment will require further study to prove the potential of betaL as a new treatment for obesity and diabetes.
###end p 64
###begin p 65
###xml 103 105 97 99 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B13">13</xref>
###xml 106 108 100 102 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B14">14</xref>
###xml 296 298 287 289 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B49">49</xref>
###xml 834 840 <span type="species:ncbi:9606">humans</span>
Previous studies showed that betaL inhibits tumorigenesis and that NQO1 mediates this effect of betaL (13,14). Interestingly, the cytotoxic effect of betaL was prominently observed in cultured cancer cells, whereas it was barely detectable in normal primary cultured cells (supplemental Fig. 7) (49). Although primary cultured MEFs showed strong resistance to betaL cytotoxicity, approximately10% of the MEFs underwent cell death (supplemental Figs. 7 and 8). This phenomenon was completely suppressed by adding palmitate to the culture medium (supplemental Fig. 8), suggesting that increased palmitate oxidation compensates betaL cytotoxicity. These data suggest that betaL-induced cell death occurs selectively in cancer cells that exhibit reduced mitochondrial oxidative phosphorylation. Although the systemic toxicity of betaL in humans has not been fully established, ARQ501, a synthetic version of betaL, has been subjected to phase I and II clinical trials and only mild adverse effects such as anemia and fatigue have been observed. It is indispensable to evaluate the systemic toxicity of betaL using different administration routes, formulas, and exposure times.
###end p 65
###begin title 66
Supplementary Material
###end title 66
###begin title 67
Online-Only Appendix
###end title 67
###begin p 68
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
###end p 68
###begin title 69
Acknowledgments
###end title 69
###begin p 70
This research was supported by the Korea Science and Engineering Foundation (KOSEF) (M10753020001-07N5302-0110), the Ministry of Education, Science and Technology, MarineBio Research Grant B10400207A290100210, and a Ministry of Maritime and Fisheries and KT&G grant, Korea. J.H.H. and Y.K.K. were supported by the second phase of the BK21 program, Ministry of Education, Korea. I.K.L. was supported by the National Research Laboratory program (grant M106 00000271-06J000-27110) from KOSEF, Ministry of Education, Science and Technology, Korea. J.C. was supported by a National Creative Research Initiatives grant (M01080206) from KOSEF, Ministry of Education, Science and Technology, Korea.
###end p 70
###begin p 71
No potential conflicts of interest relevant to this article were reported.
###end p 71
###begin p 72
We thank Young Mi Kang, Ki Nam Min, and Jong Kuk Park for technical assistance and animal care.
###end p 72
###begin title 73
REFERENCES
###end title 73
###begin article-title 74
The metabolic syndrome: time for a critical appraisal: joint statement from the American Diabetes Association and the European Association for the Study of Diabetes.
###end article-title 74
###begin article-title 75
Abdominal obesity and metabolic syndrome.
###end article-title 75
###begin article-title 76
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
###end article-title 76
###begin article-title 77
###xml 108 112 <span type="species:ncbi:10118|species:ncbi:10116">rats</span>
Sustained peripheral expression of transgene adiponectin offsets the development of diet-induced obesity in rats.
###end article-title 77
###begin article-title 78
Calorie restriction-the SIR2 connection.
###end article-title 78
###begin article-title 79
AMP-activated protein kinase as a drug target.
###end article-title 79
###begin article-title 80
AMP-activated protein kinase: ancient energy gauge provides clues to modern understanding of metabolism.
###end article-title 80
###begin article-title 81
Metabolic control through the PGC-1 family of transcription coactivators.
###end article-title 81
###begin article-title 82
Sirtuins as potential targets for metabolic syndrome.
###end article-title 82
###begin article-title 83
###xml 44 48 <span type="species:ncbi:10090">mice</span>
Resveratrol improves health and survival of mice on a high-calorie diet.
###end article-title 83
###begin article-title 84
The new life of a centenarian: signalling functions of NAD(P).
###end article-title 84
###begin article-title 85
The power to reduce: pyridine nucleotides-small molecules with a multitude of functions.
###end article-title 85
###begin article-title 86
Regulation of genes encoding NAD(P)H:quinone oxidoreductases.
###end article-title 86
###begin article-title 87
NAD(P)H:Quinone oxidoreductase activity is the principal determinant of beta-lapachone cytotoxicity.
###end article-title 87
###begin article-title 88
Capillary LC-MS for high sensitivity metabolomic analysis of single islets of Langerhans.
###end article-title 88
###begin article-title 89
Single-sample preparation for simultaneous cellular redox and energy state determination.
###end article-title 89
###begin article-title 90
SRC-1 and TIF2 control energy balance between white and brown adipose tissues.
###end article-title 90
###begin article-title 91
Metabolic stress and altered glucose transport: activation of AMP-activated protein kinase as a unifying coupling mechanism.
###end article-title 91
###begin article-title 92
Stearoyl-CoA desaturase 1 deficiency increases fatty acid oxidation by activating AMP-activated protein kinase in liver.
###end article-title 92
###begin article-title 93
###xml 82 86 <span type="species:ncbi:10090">mice</span>
Glucose and fat metabolism in adipose tissue of acetyl-CoA carboxylase 2 knockout mice.
###end article-title 93
###begin article-title 94
Determination of short-chain acyl-coenzyme A esters by high-performance liquid chromatography.
###end article-title 94
###begin article-title 95
ACE inhibitors promote nitric oxide accumulation to modulate myocardial oxygen consumption.
###end article-title 95
###begin article-title 96
###xml 62 67 <span type="species:ncbi:10090">mouse</span>
Fat apoptosis through targeted activation of caspase 8: a new mouse model of inducible and reversible lipoatrophy.
###end article-title 96
###begin article-title 97
###xml 54 58 <span type="species:ncbi:10090">mice</span>
Leptin-independent hyperphagia and type 2 diabetes in mice with a mutated serotonin 5-HT2C receptor gene.
###end article-title 97
###begin article-title 98
###xml 0 5 <span type="species:ncbi:10090">Mouse</span>
Mouse type I IFN-producing cells are immature APCs with plasmacytoid morphology.
###end article-title 98
###begin article-title 99
beta-Lapachone: synthesis of derivatives and activities in tumor models.
###end article-title 99
###begin article-title 100
NAD+ and NADH in cellular functions and cell death.
###end article-title 100
###begin article-title 101
Pyridine nucleotide redox abnormalities in diabetes.
###end article-title 101
###begin article-title 102
Energy-dependent regulation of cell structure by AMP-activated protein kinase.
###end article-title 102
###begin article-title 103
A common bicyclic protein kinase cascade inactivates the regulatory enzymes of fatty acid and cholesterol biosynthesis.
###end article-title 103
###begin article-title 104
Regulation of fatty acid synthesis and oxidation by the AMP-activated protein kinase.
###end article-title 104
###begin article-title 105
Cell biology. Chewing the fat-ACC and energy balance.
###end article-title 105
###begin article-title 106
###xml 59 63 <span type="species:ncbi:10090">mice</span>
Continuous fatty acid oxidation and reduced fat storage in mice lacking acetyl-CoA carboxylase 2.
###end article-title 106
###begin article-title 107
Mechanisms controlling mitochondrial biogenesis and respiration through the thermogenic coactivator PGC-1.
###end article-title 107
###begin article-title 108
NRF-1: a trans-activator of nuclear-encoded respiratory genes in animal cells.
###end article-title 108
###begin article-title 109
Calorie restriction promotes mammalian cell survival by inducing the SIRT1 deacetylase.
###end article-title 109
###begin article-title 110
SIRT3, a mitochondrial sirtuin deacetylase, regulates mitochondrial function and thermogenesis in brown adipocytes.
###end article-title 110
###begin article-title 111
ADD1/SREBP1 promotes adipocyte differentiation and gene expression linked to fatty acid metabolism.
###end article-title 111
###begin article-title 112
Towards a molecular understanding of adaptive thermogenesis.
###end article-title 112
###begin article-title 113
The role of AMP-activated protein kinase in mitochondrial biogenesis.
###end article-title 113
###begin article-title 114
###xml 28 33 <span type="species:ncbi:4932">yeast</span>
Calorie restriction extends yeast life span by lowering the level of NADH.
###end article-title 114
###begin article-title 115
NAD+-to-NADH and NADP+-to-NADPH in cellular functions and cell death: regulation and biological consequences.
###end article-title 115
###begin article-title 116
###xml 62 67 <span type="species:ncbi:9606">human</span>
The expression of NAD(P)H:quinone oxidoreductase 1 is high in human adipose tissue, reduced by weight loss, and correlates with adiposity, insulin sensitivity, and markers of liver dysfunction.
###end article-title 116
###begin article-title 117
The AMP-activated protein kinase-fuel gauge of the mammalian cell?
###end article-title 117
###begin article-title 118
Ca2+/calmodulin-dependent protein kinase kinase-beta acts upstream of AMP-activated protein kinase in mammalian cells.
###end article-title 118
###begin article-title 119
Calmodulin-dependent protein kinase kinase-beta is an alternative upstream kinase for AMP-activated protein kinase.
###end article-title 119
###begin article-title 120
Targeted deletion of AIF decreases mitochondrial oxidative phosphorylation and protects from obesity and diabetes.
###end article-title 120
###begin article-title 121
Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1alpha.
###end article-title 121
###begin article-title 122
Selective killing of cancer cells by beta-lapachone: direct checkpoint activation as a strategy against cancer.
###end article-title 122

